Daiwa Capital Markets Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price

by · The Markets Daily

Abbott Laboratories (NYSE:ABT – Get Free Report) had its target price dropped by equities research analysts at Daiwa Capital Markets from $136.00 to $113.00 in a research note issued on Friday,MarketScreener reports. The brokerage currently has an “outperform” rating on the healthcare product maker’s stock. Daiwa Capital Markets’ price objective would suggest a potential upside of 3.37% from the stock’s current price.

Other research analysts have also issued research reports about the company. Raymond James Financial lowered their price objective on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Citigroup lowered their price target on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Royal Bank Of Canada reduced their price objective on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Weiss Ratings lowered shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday. Finally, Evercore ISI decreased their price target on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $138.40.

Get Our Latest Analysis on ABT

Abbott Laboratories Price Performance

Shares of ABT opened at $109.31 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. The firm has a market cap of $190.08 billion, a PE ratio of 29.39, a PEG ratio of 1.69 and a beta of 0.72. Abbott Laboratories has a twelve month low of $105.27 and a twelve month high of $141.23. The firm’s 50 day moving average price is $122.77 and its 200 day moving average price is $127.49.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. The business had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. Abbott Laboratories’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, research analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Institutional Trading of Abbott Laboratories

Institutional investors and hedge funds have recently modified their holdings of the company. IMG Wealth Management Inc. increased its position in shares of Abbott Laboratories by 759.1% in the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after buying an additional 167 shares in the last quarter. Harbor Capital Advisors Inc. acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $27,000. Cloud Capital Management LLC bought a new stake in Abbott Laboratories in the 3rd quarter valued at $29,000. Guerra Advisors Inc acquired a new stake in Abbott Laboratories during the third quarter worth approximately $31,000. Finally, Anfield Capital Management LLC boosted its position in shares of Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after acquiring an additional 104 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Company Profile

(Get Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Featured Stories